The role of companion diagnostics in the development and use of mutation-targeted cancer therapies (original) (raw)

• Druker, B.J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
  Article CAS PubMed Google Scholar
• O'Brien, S.G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994–1004 (2003).
  Article CAS PubMed Google Scholar
• Goldman, J.M. & Melo, J.V. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451–1464 (2003).
  Article CAS PubMed Google Scholar
• Hughes, T.P. et al. for the International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423–1432 (2003).
  Article CAS PubMed Google Scholar
• Druker, B.J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001). (Published erratum appears in N. Engl. J. Med. 345, 232 (2001).)
  Article CAS PubMed Google Scholar
• Kantarjian, H. et al. for the international ST571 CML study group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645–652 (2002).
  Article CAS PubMed Google Scholar
• Talpaz, M. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99, 1928–1937 (2002).
  Article CAS PubMed Google Scholar
• Sawyers, C.L. et al. Imatinib induce hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99, 3530–3539 (2002).
  Article CAS PubMed Google Scholar
• Kantarjian, H.M. et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99, 3547–3553 (2002).
  Article CAS PubMed Google Scholar
• Ottmann, O.G. et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100, 1965–1971 (2002).
  Article CAS PubMed Google Scholar
• Gabert, J. et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—A Europe Against Cancer Program. Leukemia 17, 2318–2357 (2003).
  Article CAS PubMed Google Scholar
• Rosti, G. et al. for the Study and Writing Committee of the Italian Cooperative Study Group (ICSG) on Chronic Myeloid Leukemia. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 103, 2284–2290 (2004).
  Article CAS PubMed Google Scholar
• Martinelli, G. et al. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. Ann. Oncol. 17, 495–502 (2006).
  Article CAS PubMed Google Scholar
• Wang, L., Knight, K., Lucas, C. & Clark, R.E. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 91, 235–239 (2006).
  CAS PubMed Google Scholar
• Kang, H.Y. et al. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatininb. Haematologica 91, 659–662 (2006).
  CAS PubMed Google Scholar
• Iacobucci, I. et al. Comparison between patients with philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J. Clin. Oncol. 24, 454–459 (2006).
  Article CAS PubMed Google Scholar
• Yanada, M. et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed _BCR_-_ABL_–positive acute lymphoblastic leukemia: A Phase II Study by the Japan Adult Leukemia Study Group. J. Clin. Oncol. 24, 460–466 (2006).
  Article CAS PubMed Google Scholar
• Rea, D. et al. on behalf of the Intergroupe Français des Leucémies Myéloïdes CHronique (FI ϕLMC) and of the Group for Research in Adult Lymphoblastic Leukemia (GRAALL). High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 20, 400–403 (2006).
  Article CAS PubMed Google Scholar
• Wassmann, B. et al. Alternative versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood, advance online publication 25 April 2006 (doi 10.1182/blood-2005-11-4386).
• Demetri, G.D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472–480 (2002).
  Article CAS PubMed Google Scholar
• van Oosterom, A.T. et al. European organisation for research and treatment of cancer soft tissue and bone sarcoma group. safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358, 1421–1423 (2001).
  Article CAS PubMed Google Scholar
• Diebiec-Rychter, M. et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer 40, 689–695 (2004).
  Article CAS Google Scholar
• Singer, S. et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J. Clin. Oncol. 20, 3898–3905 (2002).
  Article CAS PubMed Google Scholar
• Barthe, C., Cony-Makhoul, P., Melo, J.V. & Mahon, J.R. Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163 (2001).
  Article CAS PubMed Google Scholar
• Hofmann, W.K. et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99, 1860–1862 (2002).
  Article PubMed Google Scholar
• von Bubnoff, N., Schneller, F., Peschel, C. & Duyster, J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359, 487–491 (2002).
  Article CAS PubMed Google Scholar
• Roche-Lestienne, C. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014–1018 (2002).
  Article CAS PubMed Google Scholar
• Shah, N.P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117–125 (2002).
  Article CAS PubMed Google Scholar
• Hochhaus, A. et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16, 2190–2196 (2002).
  Article CAS PubMed Google Scholar
• Branford, S. et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276–283 (2003).
  Article CAS PubMed Google Scholar
• Burgess, M.R., Skaggs, B.J., Shah, N.P., Lee, F.Y. & Sawyers, C.L. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl. Acad. Sci. USA 102, 3395–3400 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Lomabardo, L.J. et al. Discovery of N-(2-chloro-6-methyl-phanul)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658–6661 (2004).
  Article CAS Google Scholar
• Weisberg, E. et al. Characterization of AMN107, a selective inhbitor of native and mutant Bcr-Abl. Cancer Cell 7, 129–141 (2005).
  Article CAS PubMed Google Scholar
• Komarova, N.L. & Wodarz, D. Drug resistance in cancer: principles of emergence and prevention. Proc. Natl. Acad. Sci. USA 102, 9714–9719 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Diehl, F. et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. USA 102, 16368–16373 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Margulies, M. et al. Genome sequencing in microfabricated high-density picolitre reactions. Nature 437, 376–380 (2005). (Published corrigendum appears in Nature 441, 120 (2006).)
  Article CAS PubMed PubMed Central Google Scholar
• Shendure, J. et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science 309, 1728–1732 (2005).
  Article CAS PubMed Google Scholar
• Li, M., Diehl, F., Dressman, D., Vogelstein, B. & Kinzler, K. BEAMing up for detection and quandification or rare sequence variants. Nat. Methods 3, 95–97 (2006).
  Article CAS PubMed Google Scholar
• Torsen, T., Maerkl, S.J. & Quake, S.R. Microfluidic large-scale integration. Science 298, 580–584 (2002).
  Article CAS Google Scholar
• Slamon, D.J. et al. Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer. A phase III, multinational, randomized controlled trial. N. Engl. J. Med. 344, 783–792 (2001).
  Article CAS PubMed Google Scholar
• Piccart-Gebhart, M.J. et al. for the Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).
  Article CAS PubMed Google Scholar
• Romond, H.E. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).
  Article CAS PubMed Google Scholar
• Papaldo, P. et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann. Oncol. 17, 630–636 (2006).
  Article CAS PubMed Google Scholar
• Joensuu, H. et al. The FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809–820 (2006).
  Article CAS PubMed Google Scholar
• Tubbs, R.R. et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J. Clin. Oncol. 19, 2714–2721 (2001).
  Article CAS PubMed Google Scholar
• Press, M.F. et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J. Clin. Oncol. 20, 3095–3105 (2002).
  Article CAS PubMed Google Scholar
• Willmore, C., Holden, J.A. & Layfield, L.J. Correlation of HER2 gene amplification with immunohistochemistry in breast cancer as determined by a novel monoplex polymerase chain reaction assay. Appl. Immunohistochem. Mol. Morphol. 13, 333–341 (2005).
  Article CAS PubMed Google Scholar
• Hicks, D.G. & Tubbs, R.R. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum. Pathol. 36, 250–261 (2005).
  Article CAS PubMed Google Scholar
• Isola, J. et al. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin. Cancer Res. 10, 4793–4798 (2004).
  Article CAS PubMed Google Scholar
• Hanna, W.M. & Kwok, K. Chromogenic in-situ hybridization: a viable alterative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod. Pathol. 19, 481–487 (2006).
  Article CAS PubMed Google Scholar
• Tangrea, M.A. et al. Expression microdissection: operator-independent retrieval of cells for molecular profiling. Diagn. Mol. Pathol. 13, 207–212 (2004).
  Article PubMed Google Scholar
• Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004).
  Article CAS PubMed Google Scholar
• Saltz, L.B. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201–1208 (2004).
  Article CAS PubMed Google Scholar
• Vincenzi, B., Santini, D. & Tonini, G. Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan. Ann. Oncol. 17, 527–528 (2006).
  Article CAS PubMed Google Scholar
• Moroni, M. et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6, 279–286 (2005).
  Article CAS PubMed Google Scholar
• Lièvre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colortectal cancer. Cancer Res. 66, 3992–3995 (2006).
  Article PubMed Google Scholar
• Bonner, J.A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567–578 (2006).
  Article CAS PubMed Google Scholar
• Barber, T.D., Vogelstein, B., Kinzler, K.W. & Velculescu, V.E. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med. 351, 2883 (2004).
  Article CAS PubMed Google Scholar
• Gopal, A.K. & Press, O.W. Clinical applications of anti-CD20 antibodies. J. Lab. Clin. Med. 134, 445–450 (1999).
  Article CAS PubMed Google Scholar
• Jain, R.K., Duda, D.G., Clark, J.W. & Loeffler, J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3, 24–40 (2006).
  Article CAS PubMed Google Scholar
• Kris, M.G. et al. Efficacy of gefitinib, an ihibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J. Am. Med. Assoc. 290, 2129–2158 (2003).
  Article Google Scholar
• Fukuoka, M., Kris, M.G., Baselga, J., Ochs, J.S. & Haber, D.A. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23, 8081–8092 (2005).
  Article PubMed Google Scholar
• Shepherd, F.A. et al. The National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123–132 (2005).
  Article CAS PubMed Google Scholar
• Lynch, T.J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
  Article CAS PubMed Google Scholar
• Paez, J.G. et al. EGFR Mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
  Article CAS PubMed Google Scholar
• Pao, W. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306–13311 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Motzer, R.J., Hoosen, S., Bell, C.L. & Christensen, J.G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin. Investig. Drugs 15, 553–561 (2006).
  Article CAS PubMed Google Scholar
• Schõffski, P. et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Annals of Oncology, published online 17 January 2006 (doi:10.1093/annonc/mdj133).
  Google Scholar
• Torrance, C.J., Agrawal, V., Vogelstein, B. & Kinzler, K.W. Use of isogenic cancer cells for high-throughput screening and drug discovery. Nat. Biotechnol. 19, 940–945 (2001).
  Article CAS PubMed Google Scholar
• Weinstein, I.B. Cancer. Addiction to oncogenes–the Achilles heal of cancer. Science 297, 63–64 (2002).
  Article CAS PubMed Google Scholar
• Robert, F. et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer. J. Clin. Oncol. 22, 9089–9096 (2006).
  Google Scholar
• Thienelt, C.D. et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. 22, 8786–8793 (2005).
  Article Google Scholar
• Huang, S-F. et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 10, 8195–8203 (2004).
  Article CAS PubMed Google Scholar
• Han, S-W. et al. Predicitve and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 11, 2493–2501 (2005).
  Article CAS Google Scholar
• Mitsudomi, T. et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23, 2513–2520 (2005).
  Article CAS PubMed Google Scholar
• Kim, K-S. et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin. Cancer Res. 11, 2244–2251 (2005).
  Article CAS PubMed Google Scholar
• Tokumo, M. et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin. Cancer Res. 11, 1167–1173 (2005).
  CAS PubMed Google Scholar
• Chou, T-Y. et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin. Cancer Res. 11, 3750–3757 (2005).
  Article CAS PubMed Google Scholar
• Mu, X.L. et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin. Cancer Res. 11, 4289–4294 (2005).
  Article CAS PubMed Google Scholar
• Cortes-Funes, H. et al. On behalf of the Spanish Lung Cancer Group. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann. Oncol. 16, 1081–1086 (2005).
  Article CAS PubMed Google Scholar
• Cappuzzo, F. et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. National Can. Inst. 97, 643–655 (2005).
  Article CAS Google Scholar
• Takano, T. et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23, 6829–6837 (2005).
  Article CAS PubMed Google Scholar
• Bell, D.W. et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib Trials. J. Clin. Oncol. 23, 8081–8092 (2005).
  Article CAS PubMed Google Scholar
• Reily, G.J. et al. Clinical course of patients with non-small cell lung cacner and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12, 839–844 (2006).
  Article Google Scholar
• Fujiwara, Y. et al. Relationship between epidermal growth factor receptor mutations and the severity of adverse events by gefetinib in patients with advanced non-small cell lung cancer. Lung Cancer 52, 99–103 (2006).
  Article PubMed Google Scholar
• Shimato, S. et al. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefetinib. Neuro-oncol. 8, 137–144 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Han, S-W. et al. Optimization of patient selection for gefetinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin. Cancer Res. 12, 2538–2544 (2006).
  Article CAS PubMed Google Scholar
• Tsao, M-S. et al. Erlotinib in lung cancer–molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133–144 (2005).
  Article CAS PubMed Google Scholar
• Eberhard, D.A. et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin.Oncol. 23, 5900–5909 (2005).
  Article CAS PubMed Google Scholar
• Nahta, R. et al. Herceptin: mechanisms of action and resistance. Can. Lett. 232, 123–128 (2006).
  Article CAS Google Scholar
• Hynes, N.E. & Lane, H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Can. 5, 341–354 (2005).
  Article CAS Google Scholar